Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Haematologica. 2019 Dec;104(12):2443-2455. doi: 10.3324/haematol.2018.203430. Epub 2019 Apr 11.
Haematologica. 2019.
PMID: 30975914
Free PMC article.
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
Spunarova M, Tom N, Pavlova S, Mraz M, Brychtova Y, Doubek M, Panovska A, Skuhrova Francova H, Brzobohata A, Pospisilova S, Mayer J, Trbusek M.
Spunarova M, et al.
Leuk Res. 2019 Jun;81:75-81. doi: 10.1016/j.leukres.2019.04.015. Epub 2019 Apr 25.
Leuk Res. 2019.
PMID: 31054420
Item in Clipboard
Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
Olbertova H, Plevova K, Pavlova S, Malcikova J, Kotaskova J, Stranska K, Spunarova M, Trbusek M, Navrkalova V, Dvorackova B, Tom N, Pal K, Jarosova M, Brychtova Y, Panovska A, Doubek M, Pospisilova S.
Olbertova H, et al. Among authors: spunarova m.
BMC Cancer. 2022 Feb 3;22(1):137. doi: 10.1186/s12885-022-09221-z.
BMC Cancer. 2022.
PMID: 35114947
Free PMC article.
Item in Clipboard
Cite
Cite